Richard Barry Wilder MD , MS, MBA

Radiation Oncology•Boca Raton, FL

Breast Cancer, Hematologic Malignancies, Skin Cancer, Urologic Cancer

Physician Clinical Reviewer, Radiation Oncology at Evolent Health, Inc

Join to View Full Profile

Evolent Health, Inc8999 Dulcetto CtBoca Raton, FL 33496

Summary

I am a board-certified radiation oncologist who completed residency and fellowship training in 1993. I served on the NCCN Guidelines kidney and testicular cancer panel, helped to develop Moffitt Cancer Center's clinical pathways, served on the Lymphoma/Leukemia Committee wherein I wrote questions for the written exam and gave the oral exam for the for the American Board of Radiology, rose to the rank of Professor and worked as a tenured Interim Chair of the Moffitt Cancer Center in Tampa, FL, served as principal investigator on 8 clinical trials, published 92 peer-reviewed articles, gave 73 oral and poster presentations at meetings and helped to train 72 residents and fellows. Since 2016, I have worked in radiation oncology benefits management.

In January 2023, Evolent Health completed its acquisition of National Imaging Associates (NIA; also known as Magellan Health) from Centene Corporation. Centene and Evolent have a multi-year strategic partnership to expand Evolent's Oncology and End of Life solutions for health plans. NIA is a national leader in managing specialty care under risk-based, capitated relationships. Its mission is to transform the delivery of specialty care by partnering with health plans and providers to drive improvements in the quality and cost of care. Currently, NIA has over 5,000 employees, including 132 MDs and RNs and 588 social workers, who work with 80 health plans that have 21 million members. In January 2023, Evolent Health completed its acquisition of NIA from Centene Corporation. As a member of Evolent Health's utilization management team, I provide timely review of radiation oncology and radiology service requests that do not initially meet the applicable medical necessity guidelines. I routinely interact with other physicians, Evolent Health's leadership and management staff as well as health plan staff.

Education & Training

Johns Hopkins University Carey Business SchoolMBA, Finance, 2006 - 2008
University of Arizona College of Medicine-TucsonResidency, Radiation Oncology, 1989 - 1993
Stanford Health CareFellowship, 1991 - 1992
Greater Baltimore Medical CenterInternship, Internal Medicine, 1988 - 1989
University of Maryland School of MedicineClass of 1988
Stanford UniversityM.S., Biological Sciences
Stanford UniversityB.S., Biological Sciences and Chemical Engineering

Certifications & Licensure

CA State Medical License 1991 - 2026
FL State Medical License 2009 - 2026
TX State Medical License 2000 - 2026
GA State Medical License 2015 - 2018
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Lifetime Service Award American Board of Radiology, 2018
Association of Residents in Radiation Oncology Teacher of the Year Award National Capital Consortium/National Cancer Institute, 2004
Departmental Honors in Biological Sciences Stanford University
Robert D. Plageman Memorial Fund Stanford Medical School
Employee Recognition Program Award for Patient Care U. C. Davis Medical Center
Join now to see all

Clinical Trials

Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer Start of enrollment: 2008 Sep 01
Completed
Phase 1

Publications & Presentations

PubMed

Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer.
Casey Liveringhouse, Austin J. Sim, Kosj Yamoah, Michael A. Poch, Richard B. Wilder
Reports of Practical Oncology and Radiotherapy. 2021-04-14
11 citations
Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer.
H Chung, Jerimy C. Polf, Shahed N. Badiyan, Matthew C. Biagioli, Daniel C. Fernandez
Journal of Applied Clinical Medical Physics. 2017-01-01
9 citations
Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Tobin Strom, Alex Cruz, Nicholas Figura, Kushagra Shrinath, Kevin Nethers
Brachytherapy. 2015-11-01

Journal Articles

Kidney cancer, version 3
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, ..., Journal of the National Comprehensive Cancer Network, 1/1/2015
Testicular Cancer, Version 2
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, ..., Journal of the National Comprehensive Cancer Network, 1/1/2015
Kidney cancer, version 2
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Li..., Journal of the National Comprehensive Cancer Network, 1/1/2014
Long-term results with radiotherapy for stage I-II follicular lymphomas
Wilder RB, Jones D, Tucker SL, Fuller, LM, Ha CS, McLaughlin P, Hess MA, Cabanillas F, Cox JD, International Journal of Radiation Oncology, Biology, Physics, 1/1/2001
Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors
Brooks JP, Albert PS, Wilder RB, Gant DA, McLeod DG, Poggi MM, Journal of Urology
High-dose rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post...
Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, and Biagioli MC, Brachytherapy
Kidney cancer
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Mar..., Journal of the National Comprehensive Cancer Network
ACR Appropriateness Criteria�: Hodgkin�s lymphoma�Unfavorable clinical stage I and II
as P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ, Journal of the American College of Radiology
Use of a tissue spacer between the prostate and rectum improves the quality of life of prostate cancer patients undergoing radiotherapy
Wilder RB, Barme GA, Gilbert RF, Holevas RE, Kobashi LI, Reed RR, Solomon RS, Walter NL, Chittenden L, Mesa AV, Agustin J, Lizarde J, Macedo JC, Ravera J, Tokita KM, Brachytherapy
Preliminary results in prostate cancer patients treated with high dose rate brachytherapy and intensity modulated radiation therapy (IMRT) vs IMRT alone
Wilder RB, Barme GA, Gilbert RF, Holevas RE, Kobashi LI, Reed RR, Solomon RS, Walter NL, Chittenden L, Mesa AV, Agustin J, Lizarde J, Macedo JC, Ravera J, Tokita KM, Brachytherapy
ACR Appropriateness Criteria�: Follow-up of Hodgkin�s lymphoma
Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ, Current Problems in Cancer
Results with accelerated partial breast irradiation in terms of ER, PR, and HER-2/neu status
Wilder RB, Curcio LD, Khanijou RK, Eisner ME, Kakkis JL, Chittenden L, Agustin J, Lizarde J, Mesa AV, Macedo JC, Ravera J, Tokita KM, International Journal of Radiation Oncology, Biology, Physics
Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer
Wilder RB, Barme GA, Gilbert RF, Holevas RE, Kobashi LI, Reed RR, Solomon RS, Walter NL, Chittenden L, Mesa AV, Agustin J, Lizarde J, Macedo J, Ravera J, Tokita KM, International Journal of Radiation Oncology, Biology, Physics
A prospective study of intrafraction prostate motion in the prone vs supine position
Wilder RB, Chittenden L, Mesa, AV, Bunyapanasarn J, Agustin J, Lizarde J, Ravera J, Tokita KM, International Journal of Radiation Oncology, Biology, Physics
Central lymphatic irradiation for stage I-III follicular lymphoma: Report from a single-institutional prospective study
Ha CS, Kong JS, Tucker SL, McLaughlin P, Wilder RB, Hess MA, Cabanillas F, Cox JD, International Journal of Radiation Oncology, Biology, Physics
Clinical implications of incorporating heterogeneity corrections in mantle field irradiation
Kirsner SM, Kudchadker RJ, Prado KL, Ha CS, Lane RG, Wilder RB, Cox JD, International Journal of Radiation Oncology, Biology, Physics
The activation profile of tumour-associated reactive T-cells differs in the nodular and diffuse patterns of lymphocyte predominant Hodgkin�s disease
Lin P, Medeiros LJ, Wilder RB, Abruzzo LV, Manning JT, Jones D, Histopathology
Second malignancies after chemotherapy and radiotherapy for Hodgkin disease
Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD, American Journal of Clinical Oncology
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II
Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD, International Journal of Radiation Oncology, Biology, Physics
Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or COP-based therapy as measured by polymerase chain reactio...
Ha CS, Lee MS, McLaughlin P, Tucker SL, Wilder RB, Cox JD, Cabanillas F, The Cancer Journal
Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma
International Journal of Radiation Oncology, Biology, Physics, The Cancer Journal
Stage III follicular lymphoma: Long-term follow-up and patterns of failure
Ha CS, Kong JS, McLaughlin P, Tucker SL, Fayad LE, Hess MA, Wilder RB, Cabanillas F, Cox JD, International Journal of Radiation Oncology, Biology, Physics
A dosimetric comparison of volumetric-modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer
Mellon EA, Javedan K, Strom TJ, Moros EG, Biagioli MC, Fernandez DC, Wasserman SG, Wilder RB, Practical Radiation Oncology
Dosimetry for radioimmunotherapy: A rapidly evolving field
Wilder RB, Shen S, DeNardo GL, Cancer Biotherapy & Radiopharmaceuticals
Treatment of cancer with intratumoral infusion of radioisotopes
Wilder RB, DeNardo GL, DeNardo SJ, International Journal of Radiation Oncology, Biology, Physics
Join now to see all

Books/Book Chapters

Textbook of Radiation Oncology
Chapter: Radioimmunotherapy
Page 1293 - 1309Wilder RB, DeNardo SJEditors: Leibel SA, Phillips TL.WB Saunders Company, Philadelphia, PA
Cancer Radioimmunotherapy - Present and Future
Chapter: Radioimmunotherapy of breast cancer
Page 389 - 410Wilder RB, DeNardo SJEditors: Riva P.Harwood Academic Publishers, Amsterdam, The Netherlands
Radiation Oncology: Rationale, Technique, Results
Chapter: Leukemias and lymphomas
Page 821 - 855Cox, JD, Ha CS, Wilder RBEditors: Cox JD, Ang KK.Mosby, St. Louis, MOEdition 8th,
Radiation Oncology: Rationale, Technique, Results
Chapter: The skin
Page 127 - 143Ang KK, Wilder RBEditors: Cox JD, Ang KK.Mosby, St. Louis, MOEdition 8th,
Textbook of Radiation Oncology
Chapter: Radiation Oncology: Rationale, Technique, Results
Page 1483 - 1502Wilder RB, Margolis LWEditors: Leibel SA, Phillips TL.WB Saunders Company, Philadelphia, PAEdition 2nd,
The Difficult Case in Head and Neck Cancer Surgery
Chapter: Advances in radiotherapy for head and neck cancer
Page 430 - 446Chou RH, Wilder RBEditors: Donald PJ.Thieme Publishers - Verlag, New York, NYEdition 2nd,
Essentials and Updates in Urologic Oncology
Chapter: Radiotherapy preservation strategies for bladder cancer
Page 377 - 392Wilder RB, Biagioli MC, Sexton WJ, Fishman MN, Chuong MDEditors: Spiess PE.Nova Science Publishers, Inc., New York, NYEdition 1st,
Join now to see all

Lectures

Phase III RTOG protocols for head and neck cancer
U. C. Davis Medical Center, Sacramento, CA - 1/21/1996
Controversies in prostate cancer diagnosis and treatment, Presentation for outside referring physicians
Moffitt International Plaza, Tampa, FL
Intermediate grade and high grade non-Hodgkin�s lymphomas
Moffitt Cancer Center, Tampa, FL
Post-prostatectomy adjuvant vs. salvage radiotherapy
Moffitt Cancer Center, Tampa, FL
Management of stages IA-IIB testicular seminoma
Moffitt Cancer Center, Tampa, FL
Bladder preservation for muscle-invasive transitional cell carcinoma of the bladder
Moffitt Cancer Center, Tampa, FL
Adjuvant and salvage IMRT in the post-prostatectomy setting
Moffitt Cancer Center, Tampa, FL
Adjuvant and salvage radiotherapy in the post-prostatectomy setting
Walter Reed Army Medical Center, Washington, DC
Radiotherapy for bladder cancer and testicular seminoma
Walter Reed Army Medical Center, Washington, DC
Definitive radiotherapy for prostate cancer
Walter Reed Army Medical Center, Washington, DC
Treatment of arteriovenous malformations with stereotactic radiosurgery
Is there still a role for radiotherapy alone for nonbulky, stage IA-IIA Hodgkin�s disease?
Non-Hodgkin�s lymphomas
Follicular lymphomas; Hodgkin�s disease and non-Hodgkin�s lymphoma case presentations
Diffuse lymphomas
Methods of improving the efficacy of radioimmunotherapy
Extreme Hypofractionation and Hypofractionation in Prostate Cancer
Lake Buena Vista, FL
Radiation Therapy and Dosimetry Schools
Southwestern Moncrief Cancer Center in Fort Worth, TX; The Medical Branch in Galveston, TX; The Scot
An FDA-approved prospective study of a tissue spacer gel in prostate cancer patients undergoing radiotherapy
Miami Beach, FL
Radiotherapy for non-metastatic prostate cancer
Naples, FL
Cross-linked hyaluronan gel reduces the rectal toxicity of radiotherapy for prostate cancer
Moffitt Cancer Center, Tampa, FL
Can we use radiation therapy to treat patients with large cell NHL whose maximum response is a PR?
San Juan, Puerto Rico
Advances in radiotherapeutic technique for Hodgkin�s disease
M.D. Anderson, Houston, TX
Is radiation therapy alone sufficient for selected cases of early-stage classical Hodgkin�s disease?
Washington, DC
Prostate cancer screening and NCCN Guidelines for management of non-metastatic prostate cancer
St. Joseph�s/Candler Health System, Savannah, GA
Join now to see all

Other

Radiotherapy treatment planning for testicular seminoma
Wilder RB, �Beyond the Abstract.� UroToday
http://www.urotoday.com/index.php?option=com_content&Itemid=847&catid=1158&id=56713&lang=en&view=article
1/10/2013
ACR Appropriateness Criteria�: Hodgkin�s Lymphoma�Stage III and IV
Wilder RB, Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilson LD, Yunes MJ, American College of Radiology
http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonRadiationOncologyHodgkinsWorkGroup/StageIIIandIVHodgkinsDiseaseUpdateinProgressDoc6.aspx
1/1/2011
American College of Radiology. (2011, September 1). ACR Appropriateness Criteria�: Favorable prognosis stage I-II Hodgkin�s lymphoma
Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ, American College of Radiology
http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonRadiationOncologyHodgkinsWorkGroup/FavorablePrognosisStageIandIIHodgkinsDiseaseUpdateinProgressDoc1.aspx
1/1/2011
A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer, �Richard B. Wilder Comments.�
Wilder RB, MDLinx
http://www.mdlinx.com/urology/news-article.cfm/5233746
Evolving post-orchiectomy treatment options for stage IS testicular seminoma patients
Wilder RB, �Beyond the Abstract.� UroToday
http://www.urotoday.com/index.php?option=com_content&Itemid=847&catid=1158&id=72829&lang=en&view=article
Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer
Wilder RB, �Beyond the Abstract.� UroToday
http://urotoday.com/index.php?Itemid=813&option=com_content&view=article&id=75654&catid=1160&lang=en
Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer
Wilder RB, �Beyond the Abstract.� UroToday
http://urotoday.com/index.php?Itemid=782&option=com_content&view=article&catid=1134&id=77920
A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer
Wilder RB, �Beyond the Abstract.� UroToday
http://urotoday.com/index.php?Itemid=782&option=com_content&view=article&catid=1134&id=80982
Join now to see all

Press Mentions

Ensuring Equitable Access to COVID-19 VaccinesDecember 1st, 2020

Committees

Chair, ASTRO's FDA Subcommittee 2015 - 2017
Member (radiation oncology representative for national guidelines), National Comprehensive Cancer Network Kidney and Testicular Cancer Panel 2010 - 2015
Member, Lymphoma/Leukemia Committee, American Board of Radiology 2002 - 2021